文章预览
SCI 25 September 2024 High-dose Furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A prospective real-world study (Journal of Thoracic Oncology, IF: 21.0) Haiyang Chen, MD, Sen Yang, MD, Lili Wang, MD, Yingxi Wu, MD, Yufeng Wu, MD, Shuxiang Ma, MD, Zhen He, MD, Cuicui Zhang, MD, Yang Liu, MD, Haoran Tang, PhD, Hang Dong, PhD, Qiming Wang, MD CORRESPONDENCE TO: qimingwang1006@126.com Introduction 引言 Leptomeningeal metastasis (LM) is one of the most severe complications of non-small cell lung cancer (NSCLC). Furmonertinib is a pan-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with a high rate of brain penetration and a wide therapeutic window. Here, we evaluated the efficacy and safety of high-dose furmonertinib in patients with EGFR-mutated NSCLC and LM. 软脑膜转移（LM）是非小细胞肺癌（NSCLC）最严重的并发症之一。伏美替尼是一种泛表皮生长因子受体（EGFR）酪氨酸
………………………………
